1. Company Overview
Every step is a data point — and CiKLux is the company turning that data into the next standard of care. Guided by its mission, "Find the Right Way," CiKLux Inc. has engineered a proprietary sensing technology that reads real-time gait patterns purely from micro-fluctuations in a treadmill's AC power line — no wearables, no friction, no compromise on accuracy.
That technology is backed by a defensible IP portfolio of 15 assets: 6 registered patents in Korea, 1 registered patent in the U.S., 1 pending application, 2 registered trademarks, and 5 software copyrights. The team is led by CEO Dr. Hyun Sang Cho (Ph.D., Information & Communications Engineering, KAIST), who previously led ESS product strategy at Samsung SDI and headed SK D&D's Smart Grid Research Center — flanked by veteran operators in clinical trials, data science, and medical device development. The platform's rigor has been peer-validated with three Best Paper Awards from the Korea Information Science Society (2020, 2022, 2024), and CiKLux has built a clinical network spanning Seoul National University Hospital's Open Innovation program, Pusan National University Hospital's Medical Device Usability Test Center, and Ewha Womans University Mokdong Hospital's Open Lab — a runway already built for expansion into SaMD and Digital Therapeutics (DTx).
Our flagship product, Elegaiter, wasn't built in a lab — it was built to solve a problem the fitness industry was already telling us it had. Commercial traction is already underway through a signed partnership with JOABRO, a nationwide fitness franchise with 15 active locations. Elegaiter has since earned official KC certification (Cert. No. JH04228-26001), formally reaching TRL 9 — Final Commercialization — the industry's highest maturity benchmark. Translation for investors: hardware risk is off the table, and CiKLux is production-ready today.
We're not stopping at hardware. As real-world usage data scales, our analytics engine compounds in value — evolving Elegaiter from a device into a proprietary data platform. At this Meet-up, CiKLux is raising a Seed round to fund go-to-market marketing and the prototyping and certification work required for international expansion, while building relationships with fitness and healthcare partners across North America who want in on the ground floor.
2. Product & Service Overview
Landmark public-health research published in The Lancet and JAMA is unambiguous: sustaining good health requires at least 8,000 steps a day — roughly 70 minutes, or 6 kilometers, of walking. But outdoor walking is constantly disrupted by air quality, weather, and after-dark safety concerns, and its default indoor substitute — the plain treadmill — offers zero feedback and even less motivation. The result shows up in the numbers the industry doesn't like to talk about: more than half of new gym members churn within three months, driven largely by a lack of gait-correction feedback and sustained motivation. This is the fitness industry's most common, most expensive, and most solvable retention problem — and category leaders like Peloton, Zwift, and Yafit haven't touched it, because they're built around cycling, not walking, the single most fundamental form of human movement.
Elegaiter (Electric Gait Analyzer) closes that gap. The mechanics are elegantly simple: plug our proprietary JAWS sensor into any treadmill's power outlet — no wearables, no body sensors, no setup friction — and it instantly reads steps-per-minute, gait type (walking, running, limping), and left/right stride intensity by decoding micro-changes in AC current waveforms. Regardless of brand or model, a single $100 adapter (~KRW 150,000) turns any treadmill into an immersive digital health device. And to preempt the question every investor asks — how do you standardize data across treadmills with wildly different motors, belts, and wear levels? — the answer is our proprietary software layer: an intelligent real-time calibration engine that normalizes for mechanical variance across brands and machine age, delivering consistent, investment-grade accuracy on any hardware, anywhere. Users see it all instantly through a companion mobile app — stride balance, stability, and joint-health indicators — wrapped in an "exergame" experience where the on-screen character takes flight the moment you break into a run. And because Elegaiter runs on an open, SDK-based architecture, third-party developers can build gaming, metaverse, and clinical content directly on top of it — turning a hardware sale into an extensible ecosystem play.
This isn't a prototype pitch. Elegaiter has already earned official KC certification (Cert. No. JH04228-26001) and formally hit TRL 9 — Final Commercialization, the highest technology-readiness tier available — meaning regulatory risk is fully cleared and the only remaining steps are scale manufacturing and global rollout. For investors, that's the difference between funding a bet and funding a turnkey, ready-to-deploy business. And we're just getting started: as our validated hardware scales into the field, every session adds to a growing proprietary dataset that continuously sharpens our gait-pattern algorithms. We've deliberately built Elegaiter for accessibility, not for hospital procurement cycles — democratizing precision gait data for the mass fitness and wellness market first, with a clear, credible path to compounding that dataset into a category-defining analytics platform.
Launched fresh in July 2026, Elegaiter is already proving demand: a signed commercial partnership with JOABRO's 15-location fitness franchise network, plus strong reception at KIMES, the MediHealthcare R&BD Fair, and the Hi-Seoul Enterprise Festival. Our beachhead market is North America's ~12 million treadmill users — an estimated $1.2B SOM — with a fast-follow path into insurance-reimbursed care via the U.S. CPT code set (98975–98981), active since 2023 for remote therapeutic monitoring. From there, the roadmap extends into SaMD and DTx applications across musculoskeletal, CNS, and metabolic conditions, targeting KRW 19.1B in revenue and an IPO by 2030. The category is being defined right now — join us at the ground floor.